CLVT · Clarivate PLC · Executive Compensation
$2.18
+0.02 (+0.69%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$1.38B
Shares
639.90M
Volume · Nov 19
718.12K
Avg daily vol (3M)
4.13M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Henry Levy | President, Life Sciences & Healthcare | Terminated | 2026-10-06 |
| Matthew Lisowski | Senior Vice President, Chief Accounting Officer | Appointed | 2026-07-29 |
| Michael Easton | Executive Vice President & Chief Financial Officer | Appointed | 2026-07-29 |
|
Jonathan Collins
“Mr. Collins' departure is not as a result of any disagreement with the Company, its management, its Board of Directors, or the Company’s independent auditors.”
|
Executive Vice President & Chief Financial Officer | Resigned | 2026-07-29 |
| Simon Webster | President, Intellectual Property | Appointed | 2026-06-08 |
|
Valeria Alberola
“Ms. Alberola confirmed that her decision to resign is due to a change in her primary employment and not as a result of any disagreement between her and the Company, its management, the Board of Directors, or any committee thereof.”
|
Board of Directors | Resigned | 2025-07-30 |
| Maroun S. Mourad | President, Intellectual Property | Appointed | 2025-07-30 |
| Kenneth Cornick | member of our Board | Appointed | 2025-07-22 |
|
Michael J. Angelakis
“Mr. Angelakis confirmed that his decision to retire is not as a result of any disagreement between him and the Company, its management, the Board, or any committee thereof.”
|
Board of Directors | Retired | 2025-02-28 |
| Matitiahu (Matti) Shem Tov | Board | Appointed | 2024-08-06 |
| Matitiahu (Matti) Shem Tov | Chief Executive Officer | Appointed | 2024-08-06 |
|
Richard Roedel
“Mr. Roedel confirmed that his decision to retire is due to health reasons and not as a result of any disagreement between him and the Company, its management, the Board of Directors, or any committee thereof.”
|
Board of Directors | Retired | 2024-07-24 |
| Steen Lomholt-Thomsen | Chief Revenue Officer | Resigned | 2023-05-09 |
| Roxane White | director | Resigned | 2022-12-20 |
| Kosty Gilis | director | Resigned | 2022-12-20 |
| Balakrishnan S. Iyer | director | Resigned | 2022-12-20 |
| Dr. Wendell E. Pritchett | member of our Board | Appointed | 2022-07-27 |
| Jerre Stead | Chief Executive Officer | Retired | 2022-07-11 |
| Jonathan Gear | Chief Executive Officer | Appointed | 2022-07-11 |
| Jonathan Gear | member of the Board of Directors | Appointed | 2022-07-11 |
| Jonathan Gear | Chief Executive Officer-Elect | Appointed | 2022-07-11 |
| Gordon Samson | Chief Product Officer | Appointed | 2022-01-10 |
| Mukhtar Ahmed | President, Science Segment | Resigned | 2022-01-10 |
| Richard Hanks | Chief Financial Officer | Terminated | 2021-12-13 |
| Michael J. Angelakis | Board member | Appointed | 2021-12-01 |
Leadership
- Matitiahu (Matti) Shem Tov CEO, Board Member
- Matti Shem Tov CEO
- Andrew M. Snyder Chairman, Board Member
- Jonathan Collins CFO
- Michael Easton CFO, Chief Accounting Officer
- Stefano Maestri CTO
- William Graff CIO
- Jaspal Chahal General Counsel
- Heather Matzke-Hamlin Chief Accounting Officer
- Matthew Lisowski Chief Accounting Officer
- Adam T. Levyn Board Member
- Anthony Munk Board Member
- Dr. Wendell E. Pritchett Board Member
- Jane Okun Bomba Board Member
- Jonathan Gear Board Member
- Kenneth Cornick Board Member
- Michael J. Angelakis Board Member
- Saurabh Saha Board Member
- Suzanne Heywood Board Member
- Usama N. Cortas Board Member
- Wendell Pritchett Board Member
Key facts
CIK
1764046
CUSIP
G21810109
13F (30d)
227 filings
208 filers
Visit website
Investor relations